Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3128214 | 1.00 | HSD11B1 (0.51) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL4649008 | 0.90 | HSD11B1 (0.57) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL4649006 | 0.90 | HSD11B1 (0.57) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL4647105 | 0.83 | HSD11B1 (0.72) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL4647096 | 0.83 | HSD11B1 (0.72) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL3137282 | 0.82 | GRM5 (0.67) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL4620646 | 0.82 | GRM5 (0.67) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL3130814 | 0.82 | MEN1 (0.56) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL3130824 | 0.82 | MEN1 (0.56) | HSD11B1MEN1KMT2ANPC1ALDH1A1 | |
| SCHEMBL3140714 | 0.82 | HSD11B1 (0.57) | HSD11B1MEN1KMT2ANPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
| EP-1896464-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006129199-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2006-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004284-A1 | Novel Heterocyclic Compounds as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM1, GRIK5 | HSD11B1 3344/4885MEN1 4669/4885KMT2A 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.